The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Dupixent dosages for asthma in children Dupixent is also prescribed ... approves a medication, it tracks and reviews side effects of the drug. If you develop a side effect while using Dupixent ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Dupixent (dupilumab) is a brand-name injectable drug prescribed for asthma, eczema, and other inflammatory conditions in some adults and children. Dupixent comes in two forms: pens and syringes.

1. Dupixent (dupilumab) for chronic obstructive pulmonary disease: The monoclonal antibody, already approved for eczema, asthma and long-term sinus congestion with nasal polyps, became the first ...

Omalizumab (Xolair; Genentech, Novartis), dupilumab (Dupixent; Regeneron, Sanofi) and mepolizumab (Nucala, GSK) have varying effectiveness among patients with asthma and obesity, Mustafa said.

Medscape Medical News, May 31, 2024 EMA Backs Approving Sanofi's Dupixent for 'smoker's Lungs', FDA Extends Review Sanofi and ... 2024 The Primary Care Show 2024 Asthma: Reduce Reliance on the ...

Sales of Dupixent (dupilumab) rocketed 43% to €1.96 billion ($2 billion) – ahead of analyst expectations – driven by buoyant demand in its atopic dermatitis and severe asthma indications ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Dupixent (dupilumab), used for allergic disease such as eczema and asthma, according to Nature Reviews Drug Discovery. Ozempic and Dupixent were, respectively, the No. 4 and No. 8 top pharma drugs ...